Clinical Trials Logo

Clinical Trial Summary

After breast cancer (BC) screening was introduced for all Swedish women in 1989-90 the number of early invasive BC, clin N0 rose dramatically. For these BC it was known that only 10 % or less was N+ after axillary dissection and the morbidity for axillary surgery was substantial. Omitting axillary dissection in a randomized trial was ruled out because of anticipated few events. A national cohort was decided for invasive unifocal BC, histological grade 1 or 2, T=max 10mm, free margins, clin node neg. No axillary dissection should be undertaken. This was before the Sentinel Node era. Adjuvant treatment could be given according to regional guidelines for early breast cancer. Not uniform concerning postoperative radiotherapy and antihormonal treatment. Follow-up was clinical the first 5 years with mammography and then by hospital records and national Death register. Primary aim: Number of axillary recurrence and BC specific survival.


Clinical Trial Description

After national breast cancer screening was introduced in Sweden in 1989-90 the number of early invasive BC, clin N0 rose dramatically. Only 10 % or less of these was N+ after axillary dissection with a substantial morbidity after the axillary intervention. Omitting axillary dissection in a randomized trial was ruled out because of anticipated few events. A national cohort was decided for invasive unifocal BC, Screening or clinical diagnosis were eligible, only histological grade 1 or 2, T=max 10mm, free margins , clinical node negative. No axillary dissection should be undertaken, only radical removal of the breast cancer. (Note; This was before the Sentinel Node era). Adjuvant treatment could be given according to regional guidelines for early breast cancer as no regular national guidelines existed then concerning postoperative radiotherapy and antihormonal treatment. Chemotherapy was not recommended to this type of breast cancer. Follow-up was done by the treating surgeon the first 5 years including mammography. Then hospital records including mammography and reports from Pathology and Oncology and Death register were followed at intervals 5, 10 and 15 years. Primary aim: Number of axillary recurrence and distant metastases/ BC specific survival. Correlation to adjuvant therapy. Inclusion started in 1997 and ended in 2002. 1584 patients were included. If the axillary recurrence rate was more than 1% per year the first five years the inclusion should be stopped. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03669705
Study type Observational
Source Lund University
Contact
Status Completed
Phase
Start date September 15, 1997
Completion date December 31, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT03664895 - Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) Phase 3
Recruiting NCT05505357 - Omission of Breast Surgery for Breast Cancer Patients With pCR on MRI and Vacuum-assisted Biopsy After NST (OPTIMIST) N/A
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Recruiting NCT05877859 - Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Active, not recruiting NCT04398914 - Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Recruiting NCT05351424 - AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc N/A
Active, not recruiting NCT03627988 - Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy. Phase 2
Completed NCT05300412 - The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer
Recruiting NCT04999917 - Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer N/A
Recruiting NCT05910398 - Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer Phase 3
Completed NCT05019989 - Trial of Diet, Physical Activity and Breast Cancer Recurrences: the DIANA-5 Study N/A
Recruiting NCT06144944 - Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer Phase 3
Recruiting NCT04891068 - BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer Phase 2
Recruiting NCT05939310 - Fluorescence Guided Surgery in Breast Cancer - The MARGIN-2 Study N/A
Recruiting NCT06401304 - Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value)
Not yet recruiting NCT06268665 - Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Phase 2
Completed NCT05463276 - The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study
Completed NCT04729647 - Immature Granulocyte Count and Delta Neutrophil Index Factors for Axillary Metastasis of Breast Cancer N/A
Active, not recruiting NCT06234488 - Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
Recruiting NCT00437879 - Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment.